At the European Society of Cardiology Congress 2024, Edwards Lifesciences (EW) announced the results from the RHEIA Trial — the first-ever study focused exclusively on women receiving transcatheter aortic valve implantation (TAVI). The outcome revealed that Edwards SAPIEN 3 or SAPIEN 3 Ultra valves have led to superior outcomes for women compared with those receiving surgical aortic valve replacement (SAVR). The latest development will strongly boost the company's Transcatheter Aortic Valve Replacement (TAV ...

. . . East West Petroleum Announces Cash Distribution to Shareholders by Way of Return of Capital August 29, 2024 7:00 AM EDT | Source: East West Petroleum Corp. Vancouver, British Columbia--(Newsfile Corp. - August 29, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that, further to its news release of August 16, 2024, it will distribute to holders of common shares of the Company ("Shareholders") by way of a return of capital, $0.03 per common share of the ...

A month has gone by since the last earnings report for Edwards Lifesciences (EW) . Shares have added about 19.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Edwards Lifesciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Edwards Lifesciences Q2 Earnings ...

Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that its shareholders have today approved its previously announced return of capital by way of a reduction in stated capital of the Company. In accordance with the special resolution passed by the shareholders, the board of directors of the Company has determined that the stated capital of the Company, which is currently $39,868,761, will be reduced by up to $3 mill ...

Edwards Lifesciences' (EW) robust potential in the TAVR (Transcatheter Aortic Valve Replacement) business is poised to help it grow in the upcoming quarters. The company's decision to sell the Critical Care arm supports its goal of developing a comprehensive structural heart portfolio. Also, sound solvency instills optimism. However, rising costs and adverse currency impacts remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has dropped 11.3% against the 9.3% rise of the indu ...

The Company has prepared and mailed its management information circular (the "Circular") and related proxy materials (collectively, the "Meeting Materials") to its shareholders ("Shareholders") in connection with the special meeting of Shareholders to be held at 10:00 a.m. (Vancouver time) on August 16, 2024 (the "Meeting"). The Meeting Materials have been mailed to Shareholders of record as of July 10, 2024 (the "Record Date"). At the Meeting, Shareholders will be asked to consider, and if deemed advisable ...

Have you assessed how the international operations of Edwards Lifesciences (EW) performed in the quarter ended June 2024? For this medical device maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. Fo ...

The S&P 500 slipped 0.5% on Thursday, July 25, as tech stocks faltered for a second straight day even as data showed an uptick in GDP growth. Edwards Lifesciences shares plunged after the medtech firm cut its sales forecast for a critical heart device. Shares of ServiceNow moved higher following a strong earnings report buoyed by subscription revenue growth. Although indications of persistent economic strength temporarily took the spotlight on Thursday, boosting stocks in intraday trading, the concerns abou ...

Quest Diagnostics, carrying a Zacks Rank #2, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion exceeded the Zacks Consensus Estimate by 0.5%. DGX's historical five-year earnings growth rate of 7.4% compares favorably with the industry's 4.2%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 3.31%. Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 7 ...

Edwards Lifesciences (NYSE:EW) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents. This just beats out Wall Street's estimate of 69 cents per share. It's also better than the 66 cents per share reported in the same period of the year prior. However, the company's revenue of $1.63 billion failed to impress investors. That comes in below analysts' estimate of $1.65 billion for the perio ...